RNA foci

This program centers on the discovery of small molecules able to disrupt RNA foci, a key cellular characteristic of patient-derived cells with myotonic dystrophy type 1. This program is a collaboration between Dr. Pascal Chartrand from the Université de Montréal and NuChem Therapeutics. Small molecules were identified which were active in patient-derived cells.